CTI Clinical Trial and Consulting Services Opens Geel, Belgium Office
CTI announced that is has opened an office in Geel, Belgium.
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces that is has opened an office in Geel, Belgium. The office is opened through the wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Belgium SPRL. This is the company’s sixth new office opened this year, with additional new offices expected to be announced in the next several months.
“We have had CTI employees in Belgium for the past several years working on behalf of our pharmaceutical and biotechnology clients, but it felt like it was time to formalize an office in the country,” according to Patrick Earley, Vice President, International. “Belgium is desirable for clinical trials due to innovative regulatory agencies, as well as excellent academic centers and researchers, leading to rapid study start up timelines and high enrollment at sites.”
CTI has been working for over fifteen years in the drug development industry in North America, Europe, South America, and Pac-Asia, specializing in clinical research programs involving critically ill patient populations, and has more than 20 offices worldwide to serve more than 80 pharmaceutical, biotechnology, and medical device clients.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
